CLAIMS

What is claimed is:

1. A pharmaceutical composition, comprising:

A) a biodegradable polymer matrix, comprising a first biodegradable poly(D,L-lactide-co-glycolide) (PLGA) copolymer, a second biodegradable PLGA copolymer different from the first PLGA copolymer, and a third biodegradable PLGA copolymer different from the first and second PLGA copolymers, wherein the first, second , and third PLGA copolymers are biocompatible with one another; and

B) dexamethasone homogenously dispersed within the polymer matrix.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for intravitreal administration to a subject's eye.

3. The pharmaceutical composition of claim 1, wherein the dexamethasone comprises 35 weight percent to 45 weight percent of the pharmaceutical composition.

4. The pharmaceutical composition of claim 1, wherein the biodegradable polymer matrix comprises: 85 ± 5 wt % of a biodegradable poly(D,L-lactide-co-glycolide) copolymer having an inherent viscosity of 0.45 to 0.60 dL/g measured at 0.1% w/v in $CHCl_3$ at 25 °C with a Ubbelhode size 0c glass capillary viscometer.

5. The pharmaceutical composition of claim 1, wherein the biodegradable polymer matrix comprises: 85 ± 5 wt % of a biodegradable poly(D,L-lactide-co-glycolide) copolymer having an inherent viscosity of 0.32-0.44 dL/g measured at 0.1% w/v in $CHCl_3$ at 25 °C with a Ubbelhode size 0c glass capillary viscometer.

6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated to release dexamethasone for at least about 4 months.

7. An intravitreal implant comprising the pharmaceutical composition of any one of claims 1 to 6.

8. The intravitreal implant of claim 7, wherein the intravitreal implant is to be administered to the vitreous humor of an eye of a human.

9. The pharmaceutical composition of any one of claims 1 to 5 for use in therapy.

10. Use of the pharmaceutical composition of any one of claims 1 to 5 in the manufacture of a medicament for the treatment of an ocular disease.

11. The use of claim 10, wherein the ocular disease is macular edema, retinal vein occlusion, or uveitis.